These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26503473)

  • 1. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
    Hong DS; Kurzrock R; Falchook GS; Andresen C; Kwak J; Ren M; Xu L; George GC; Kim KB; Nguyen LM; O'Brien JP; Nemunaitis J
    Oncotarget; 2015 Dec; 6(40):43127-34. PubMed ID: 26503473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
    Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
    Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).
    Molina AM; Hutson TE; Larkin J; Gold AM; Wood K; Carter D; Motzer R; Michaelson MD
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):181-9. PubMed ID: 24190702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
    Agarwala SS; Kirkwood JM
    Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
    J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
    Ranson M; Hersey P; Thompson D; Beith J; McArthur GA; Haydon A; Davis ID; Kefford RF; Mortimer P; Harris PA; Baka S; Seebaran A; Sabharwal A; Watson AJ; Margison GP; Middleton MR
    J Clin Oncol; 2007 Jun; 25(18):2540-5. PubMed ID: 17577032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
    Warren KE; Aikin AA; Libucha M; Widemann BC; Fox E; Packer RJ; Balis FM
    J Clin Oncol; 2005 Oct; 23(30):7646-53. PubMed ID: 16234526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
    Rangwala R; Leone R; Chang YC; Fecher LA; Schuchter LM; Kramer A; Tan KS; Heitjan DF; Rodgers G; Gallagher M; Piao S; Troxel AB; Evans TL; DeMichele AM; Nathanson KL; O'Dwyer PJ; Kaiser J; Pontiggia L; Davis LE; Amaravadi RK
    Autophagy; 2014 Aug; 10(8):1369-79. PubMed ID: 24991839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide and cisplatin in avdanced malignant melanoma.
    Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G
    Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
    Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
    Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
    Kaufmann R; Spieth K; Leiter U; Mauch C; von den Driesch P; Vogt T; Linse R; Tilgen W; Schadendorf D; Becker JC; Sebastian G; Krengel S; Kretschmer L; Garbe C; Dummer R;
    J Clin Oncol; 2005 Dec; 23(35):9001-7. PubMed ID: 16260697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration.
    Marzolini C; Decosterd LA; Shen F; Gander M; Leyvraz S; Bauer J; Buclin T; Biollaz J; Lejeune F
    Cancer Chemother Pharmacol; 1998; 42(6):433-40. PubMed ID: 9788568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.
    Dhodapkar M; Rubin J; Reid JM; Burch PA; Pitot HC; Buckner JC; Ames MM; Suman VJ
    Clin Cancer Res; 1997 Jul; 3(7):1093-100. PubMed ID: 9815788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
    Awada A; Gil T; Sales F; Dubuisson M; Vereecken P; Klastersky J; Moerman C; de Valeriola D; Piccart MJ
    Anticancer Drugs; 2004 Jun; 15(5):499-502. PubMed ID: 15166625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
    Gander M; Leyvraz S; Decosterd L; Bonfanti M; Marzolini C; Shen F; Liénard D; Perey L; Colella G; Biollaz J; Lejeune F; Yarosh D; Belanich M; D'Incalci M
    Ann Oncol; 1999 Jul; 10(7):831-8. PubMed ID: 10470431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study.
    Guillot B; Khamari A; Cupissol D; Delaunay M; Bedane C; Dreno B; Picot MC; Dereure O
    Melanoma Res; 2008 Apr; 18(2):141-6. PubMed ID: 18337651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
    Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
    Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.